Patent · US Active

Pharmaceutical formulations of desmopressin

US9504647B2 · kind B2 · utility

2Cited by

84References

18Claims

0Family size

Assignee

Ferring B.V. · NL

Inventors

Anders Nilsson · Västerås, SE
Hans Lindner · Leichlingen, DE
Jørgen Wittendorff · Copenhagen, DK

Key dates

Filing date	Nov 20, 2015
Grant date	Nov 29, 2016
Priority date	—
Expiry date	Nov 20, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/2095
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.